Regencell Bioscience Holdings Limited (RGC)
- Previous Close
92.88 - Open
101.66 - Bid 180.84 x 100
- Ask 164.74 x 200
- Day's Range
99.64 - 250.00 - 52 Week Range
3.03 - 250.00 - Volume
507,082 - Avg. Volume
708,903 - Market Cap (intraday)
1.965B - Beta (5Y Monthly) -4.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.54 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
www.regencellbioscience.com12
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RGC
View MorePerformance Overview: RGC
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGC
View MoreValuation Measures
Market Cap
1.21B
Enterprise Value
1.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
147.06
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.11%
Return on Equity (ttm)
-43.18%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.3M
Diluted EPS (ttm)
-0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
7.96M
Total Debt/Equity (mrq)
1.04%
Levered Free Cash Flow (ttm)
-1.88M